Edwards Lifesciences Corporation — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. Although the request identifies 2015 Q4, this 10-K reports the full year and includes unaudited fourth-quarter results. Edwards develops and sells heart valve therapies and critical-care monitoring products worldwide.
Financial performance and liquidity
- FY2015 revenue: $2.494 billion, up 7.4% from $2.323 billion in 2014. U.S. sales rose 20.6% to $1.263 billion; international sales declined 3.5% to $1.231 billion, including adverse currency effects.
- Product revenue: Transcatheter Heart Valve Therapy (THV) was $1.180 billion, up 25.1%; Surgical Heart Valve Therapy was $785.0 million, down 5.0%; Critical Care was $528.4 million, down 4.5%.
- Profitability: Gross profit was $1.877 billion and gross margin was 75.2%, compared with 73.1% in 2014. Net income was $494.9 million, down 39.0%; diluted EPS was $2.25, down 39.8%. The prior-year comparison included a $750 million Medtronic settlement payment.
- Fourth quarter: Revenue was $671.1 million, gross profit $495.2 million, net income $140.7 million, and diluted EPS $0.64.
- Cash flow: Operating cash flow was $549.7 million, versus $1.022 billion in 2014. Capital expenditures were $102.7 million. Investing cash outflow was $316.1 million and financing cash outflow was $158.6 million. Year-end cash and cash equivalents were $718.4 million.
- Liquidity and debt: Cash and short-term investments totaled $1.225 billion; current assets were $2.048 billion and current liabilities $476.2 million. Long-term debt carrying value was $599.9 million, consisting primarily of $600 million of 2.875% notes due in 2018. The company had no borrowings under its $750 million credit agreement and reported covenant compliance.
- Other metrics: R&D expense was $383.1 million, or 15.4% of revenue. The company repurchased $280.1 million of stock during 2015 and declared no cash dividends.
Material changes versus 2014
- THV growth, supported by SAPIEN XT and SAPIEN 3 launches, was the main driver of revenue growth; THV represented 47% of sales versus 41% in 2014.
- Gross margin improved 2.1 percentage points, reflecting favorable currency and hedging effects and a richer THV mix, partly offset by manufacturing investments.
- Net income fell despite sales growth because 2014 included the $750 million Medtronic settlement payment, recorded as litigation income. The settlement also provides quarterly royalties through April 2022, subject to stated terms.
- Currency movements reduced reported sales in 2015, particularly in Europe and Japan. Edwards attributed $71.2 million of lower THV sales, $59.7 million of lower surgical valve sales, and $41.3 million of lower Critical Care sales to currency effects.
- Edwards acquired CardiAQ, a transcatheter mitral valve developer, for $348 million net of purchase-price adjustments, with a possible additional $50 million milestone payment. The acquisition added $190 million of in-process R&D and $258.9 million of goodwill.
Outlook, commentary, and risks
- Management emphasized innovation and pipeline investment as drivers of long-term growth; the filing provides no specific forward-year revenue or earnings guidance.
- In 2015, Edwards received FDA approval for SAPIEN 3 for high-risk patients with severe symptomatic aortic stenosis and approval for SAPIEN XT valve-in-valve procedures. The company continued development of mitral and tricuspid therapies and other structural-heart products.
- The FDA’s 2013 warning letter concerning quality-system execution at the Draper, Utah facility remained a disclosed regulatory matter. Edwards reported completing agreed action-plan items for SAPIEN XT delivery systems and components and obtaining an FDA variance for those products in 2014.
- Key risks include regulatory approval delays or restrictions, product quality and liability events, clinical-trial uncertainty, dependence on successful new-product launches, competition and pricing pressure, reimbursement changes, supplier concentration, currency exposure, and international operations.
- Uncertain tax positions were significant: gross unrecognized tax benefits were $216.1 million, and an unresolved U.S.-Switzerland advance pricing agreement and IRS pre-filing matter could cause a material change in the balance. The filing does not provide a reliable estimate of timing or amount of resolution.
- Boston Scientific brought patent claims concerning SAPIEN 3 sealing technology in Germany and the U.K.; Edwards disputed the claims and pursued related patent actions. The company said it could not estimate potential losses for certain legal contingencies.
- The medical-device excise tax was suspended for 2016 and 2017 and was scheduled to resume in 2018 under the law then in effect. A February 2016 accelerated repurchase agreement for $325 million is a subsequent event, not a 2015 cash flow.
Important facts for investors to verify
- How much of future THV growth depends on SAPIEN 3 adoption, expanded indications, and successful development of mitral and tricuspid products?
- What are the continuing effects of foreign exchange on sales, margins, and cash generation, and how effective are the company’s hedges?
- What is the status and potential financial effect of the Utah FDA warning-letter matters, the Boston Scientific patent disputes, and the significant tax agreements and audits?
- Can operating cash flow remain strong without the one-time 2014 settlement receipt, while funding R&D, acquisitions, capital spending, and share repurchases?
- What are the eventual costs and commercial prospects of CardiAQ, including the contingent milestone, and how should investors assess the acquired in-process R&D valuation?